Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Volkmar Boehme(Asklepios Klinik St. Georg), Norbert Schmitz(University Hospital Münster), Markus Loeffler(Leipzig University), Ulrich Kaiser(University of Applied Sciences Landshut), Samira Zeynalova(Leipzig University), Marita Kloess, Michael Pfreundschuh(Saarland University)
Annals of Oncology
October 4, 2006
10.1093/annonc/mdl327
Cited by 280

Related Papers

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes
|Nature Communications|2018|1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k